⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan Christian X. Cruz Pico Kurt W. Evans Maria Gabriela Raso Yasmeen Q. Rizvi Xiaofeng Zheng Dhruv Chachad Timothy P. DiPeri Bailiang Wang Stephen M. Scott Ming Zhao Argun Akçakanat Antje M. Wengner Timothy A. Yap Funda Meric‐Bernstam

View Full Paper

Ask AI

Bookmark

Share

Key Points

Elimusertib treatment demonstrates alterations in genomic features of tumors derived from patient-derived xenografts (PDXs).
ATM IHC showed variations in tumor response to elimusertib among treated PDX models, highlighting the role of DNA damage response pathways.
Analysis focused on the efficacy of atr kinase inhibitors like elimusertib, examining its impact on tumors with specific genomic alterations.
Findings suggest that understanding genomic changes could improve therapeutic strategies for treating tumors with DNA damage responses.

Implication

Observational analysis shows ATM IHC and genomic alterations in PDXs treated with elimusertib, indicating significant treatment effects.

Abstract

Supplementary Figure 4. ATM IHC and genomics of PDXs treated with elimusertib 40 mg/kg.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02932 https://doi.org/10.1158/1535-7163.30028666

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
2Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
3Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
4Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
5Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025